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Abstract.17
Background: The genetic variant rs9923231 (VKORC1) is associated with differences in the coagulation of blood and
consequentially with sensitivity to the drug warfarin. Variation in VKORC1 has been linked in a gene-based test to
dementia/Alzheimer’s disease in the parents of participants, with suggestive evidence for an association for rs9923231





Objective: Our study aimed to investigate whether the relationship between rs9923231 and dementia persists only for certain
dementia sub-types, and if those taking warfarin are at greater risk.
22
23
Methods: We used logistic regression and data from 238,195 participants from UK Biobank to examine the relationship
between VKORC1, risk of dementia, and the interplay with warfarin use.
24
25
Results: Parental history of dementia, APOE variant, atrial fibrillation, diabetes, hypertension, and hypercholesterolemia all
had strong associations with vascular dementia (p < 4.6 × 10–6). The T-allele in rs9923231 was linked to a lower warfarin
dose (perT-allele = –0.29, p < 2 × 10–16) and risk of vascular dementia (OR = 1.17, p = 0.010), but not other dementia sub-types.





Conclusion: Our study reports for the first time an association between rs9923231 and vascular dementia, but further
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INTRODUCTION 34
Warfarin is the most prescribed anticoagulant 35
worldwide [1] and is commonly used as a treatment 36
for atrial fibrillation (AF) [2]. The drug functions by 37
inhibiting the enzyme vitamin K epoxide reductase 38
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(VKOR), effectively interfering with the vitamin K39
cycle required for coagulation of blood [3]. As a result40
of variations in age, height, weight, genotype, and41
other factors [4–6], patients vary up to 20-fold in their42
sensitivity to warfarin [7]. Clinically, the optimum43
dose is estimated using tests of blood coagulation,44
commonly the International Normalized Ratio (INR).45
The strongest genetic predictor of warfarin sensitivity46
is the gene VKORC1, which encodes for the vitamin47
K epoxide reductase subunit 1 (VKORC1) and acco-48
unts for approximately a third of the variance in49
warfarin sensitivity [3]. Three VKORC1 SNPs, rs9950
23231, rs9934438, and rs2359612—which are in51
very high linkage disequilibrium—are the best gen-52
etic predictors of warfarin sensitivity [3, 7, 8].53
In a recent genome-wide association study (GW54
AS) meta-analysis of parental dementia and case-55
control Alzheimer’s dementia (ADem) [9], VKORC156
was associated (after Bonferroni correction) with57
ADem in a gene-based test (p = 5.1 × 10–8); the T-58
allele in rs9923231, which is related to the need for59
a lower dose of warfarin, was not a genome-wide60
significant finding, but was both located within a61
genome-wide significant locus and nominally associ-62
ated with an increased risk of ADem (p = 1.8 × 10–7).63
Pure Alzheimer’s disease pathology, characterized by64
amyloid plaques and neurofibrillary tangles in the65
grey matter, is uncommon, and most patients exhibit66
a mixed pathology in which vascular factors often67
play a prominent role [10]. In fact, there is exten-68
sive evidence directly linking vascular dysfunction69
to ADem [11]. Thus, a possible explanation for the70
findings [9] is that vascular factors played a crucial71
role in a proportion of the ADem cases/family history72
cases observed. If that is the case, then there should73
be an even stronger relationship between VKORC174
and vascular dementia (VaD) that is mostly due to75
cardiovascular factors.76
Most strokes in western countries are due to occlu-77
sions in blood vessels (ischemic), and some are due78
to ruptures in blood vessels (hemorrhagic) [12]. If79
carriers of the T-allele in rs9923231 experience a80
reduction of blood coagulation and subsequent seq-81
uential minor hemorrhagic strokes, the resulting pa-82
thology could manifest in dementia and explain the83
observed link. Furthermore, compared to non-carriers84
of the T-allele, patients with AF that carry the T-allele85
could be at an increased risk of intracerebral hem-86
orrhage and consequentially VaD when prescribed87
warfarin. Here, we study the same UK Biobank88
cohort as previously [9], but consider both individ-89
ual and parental dementia status. We test whether90
T-allele status is associated with an increased risk 91
of VaD and explore whether carriers of the T-allele 92




We used data from UK Biobank, a large and 97
detailed prospective study of over 500,000 partici- 98
pants aged 37–73 that were recruited between the 99
years 2006 and 2010. UK Biobank has been described 100
in detail before [13]. The Research Ethics Committee 101
(REC) granted ethical approval for the study (ref- 102
erence 11/NW/0382) and the current analysis was 103
conducted under data application 10279. 104
Genotyping 105
Details on genotyping in the UK Biobank have 106
been reported before [14, 15]. Briefly, for 49,950 par- 107
ticipants, genotyping was performed using the UK 108
BiLEVE Axiom Array, and for 438,427 participants, 109
genotyping was performed using the UK Biobank 110
Axiom Array. The released data contained 805,426 111
markers for 488,377 participants. Further quality con- 112
trol steps were performed as previously reported [9]. 113
They included the removal of outliers, of incongru- 114
ent data points, and of related participants using a 115
relationship cut-off of 0.025 (GCTA GREML) [16]. 116
This left an unrelated cohort of 314,278 individuals 117
of white British ancestries (Fig. 1). 118
Warfarin prescription data 119
The UK Biobank obtained data on prescriptions 120
for 222,111 participants via primary care computer 121
system suppliers (EMIS Health and Vision for Scot- 122
land, and Wales, Vision and The Phoenix Partnership 123
for England) and has engaged other intermediaries 124
(Albasoft, a third-party data processor, for Scotland 125
and the SAIL databank for Wales). All participants 126
provided written consent for linkage to their health 127
records upon recruitment to UK Biobank. The data 128
were extracted in May 2017 for Scotland, in Septem- 129
ber 2017 for Wales, and in June, in July, and in 130
August 2017 for England. The data include the exact 131
dates of prescriptions, drug codes (BNF, Read v2, 132
CTV3, and dm + d), names of drugs as written on 133
the prescription, and, where available, the dosages of 134
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Fig. 1. The data cleaning procedure. The left path (orange boxes)
represents the genotyping and associated quality control, the mid-
dle path (blue box) represents the ascertainment of primary care-
and inpatient diagnoses, and the right path (yellow boxes) repre-
sents the linkage to primary care prescriptions and the cleaning
of the latter. The last two steps (grey boxes) involve the inclusion
of only those participants that were older than 60 at the end of
sampling and who passed through the left and middle paths (first
grey box, 238,195 participants), or through all three data-cleaning
paths (second grey box, 115,206 participants). All analyses that did
not include prescribing data in the models were performed using
the 238,195 participants, while the analyses that utilized warfarin
prescription history used the 115,206 participants.
without a date, and duplicate prescriptions (defined136
as identical prescriptions issued to the same person137
on the same day) were removed from the sample.138
This resulted in the removal of 1,467,547 prescrip-139
tions. Three participants were completely removed140
from the dataset (Fig. 1). Warfarin prescriptions were141
extracted by searching for the word “warfarin” under142
the name/content of each prescription. For each par-143
ticipant, we calculated warfarin use by summing the144
number of days on which warfarin was prescribed,145
and warfarin dose by averaging the prescribed dose146
over all prescriptions of warfarin.147
Disease status148
Data on diagnoses for 465,510 participants were149
obtained by the UK Biobank from two sources:150
1) from primary care similarly to the prescriptions151
described above, and 2) from hospital inpatient152
admissions data. Inpatients are defined as people who153
are admitted to hospital and occupy a hospital bed.154
These data included Hospital Episode Statistics for 155
England, Scottish Morbidity Records for Scotland, 156
and the Patient Episode Database for Wales. Peo- 157
ple with record of any dementia were included in 158
a broad dementia category of “general dementia” 159
that included ADem and VaD, as well as other types 160
of dementia. Furthermore, narrower, more specific 161
categories (ADem, VaD) were also identified. Infor- 162
mation on the codes used in the extraction of each 163
diagnosis is provided in Supplementary Table 1. We 164
excluded from our analyses all participants that were 165
60 years old or younger on the last date of sampling 166
(June 30, 2020) since dementia risk increases steeply 167
with age. Parental diagnoses were ascertained during 168
the initial assessment by asking participants about the 169
presence of “Alzheimer’s disease/dementia” for both 170
mother and father. In our analyses, the parental diag- 171
nosis of dementia was considered positive if at least 172
one parent was reported to have suffered from the 173
disorder. 174
Models 175
All analyses where the outcome variable was con- 176
tinuous were performed using linear regression; all 177
models where the outcome variable was binary were 178
performed using logistic regression. All models were 179
controlled for the assessment center in which the par- 180
ticipant was tested, the genotyping- batch and array, 181
40 genetic principal components, the age, sex, edu- 182
cation, socioeconomic deprivation, alcohol consump- 183
tion, smoking, physical activity, and body mass index 184
(BMI) of the participants. The models predicting VaD 185
were subsequently additionally controlled for APOE 186
variant, concentration of triglycerides (mmol/L), and 187
the diagnoses of hypertension, hypercholesterolemia, 188
and diabetes. All covariates were ascertained imme- 189
diately prior to or during the participants’ recruitment 190
to the UK Biobank. For education, a binary classifi- 191
cation was used that indicated whether a graduate 192
degree had been attained. For socioeconomic depri- 193
vation, the Townsend index [17] was used, where 194
higher values indicate greater socioeconomic depri- 195
vation (range in the sample: –6.3–10.8). For alcohol 196
consumption, a 6-level scale of frequency of alco- 197
hol consumption was used, where 1: “daily or almost 198
daily”, 2: “three or four times a week”, 3:“one or 199
two times a week”, 4: “one to three times a month”, 200
5: “special occasions only”, 6: “never”. For smok- 201
ing, the participants were classified as non-smokers, 202
past smokers, or current smokers. For physical activ- 203
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reduced to a 3-level scale, indicating light, moderate,205
or strenuous physical activity, as has been used before206
[18]. For APOE genotype based on the nucleotides207
at SNP positions rs429358 and rs7412, participants208
with the 3/3 haplotype were denoted as carrying209
variant 3, participants with the 2/2 or 2/3 hap-210
lotypes were denoted as carrying variant 2, and211
participants with the 3/4 or 4/4 haplotypes were212
denoted as carrying variant 4. Brain imaging data,213
including the volume of white matter hyperintensi-214
ties (WMH), were available for 18,251 participants215
in the sample. For analysis where WMH was mod-216
elled as an outcome, WMH was log-transformed217
and corrected for intracranial volume. For analyses218
where parental diagnoses were modelled as out-219
comes, the ages of each parent (current age or age220
at death) were included in the models. In all cases221
where we tested for associations between rs9923231222
(VKORC1) and any form of dementia, we assumed223
an additive genetic effect for rs99232331. All covari-224
ates were simultaneously added to the model and225
the models were not corrected for multiple com-226
parisons. The effects are reported in odds ratios227
(OR’s) or unstandardized beta-coefficients. All anal-228
yses were performed in R version 3.6.3. The code229




Among the 238,195 participants, 129,034 (54.2%) 234
were female and 109,161 (45.8%) were male 235
(Table 1). The age range at recruitment was 46–74 236
years (Fig. 2) and the median age was 60.9 years 237
(IQR = 9.1). The demographic characteristics of the 238
Fig. 2. Odds ratios for parental dementia, ADem, and VaD per
rs9923231 genotype status. Depicted are the additive effect and
the effects of each allele group. The tails represent 95% confidence
intervals for the ORs.
Table 1
Demographic characteristics of the sample
Variable Level Median (IQR) or n (%)
All General dementia ADem VaD
(n = 238,195) (n = 4259) (1531) (669)
Age 60.9 (9.1) 65.5 (5.8) 65.9 (5.3) 66.3 (4.7)
Sex Female 129,034 (54.2) 1,939 (45.5) 795 (51.9) 267 (39.9)
Male 109,161 (45.8) 2,320 (54.5) 736 (48.1) 402 (60.1)
Education Graduate degree 72,385 (30.7) 947 (22.6) 313 (20.9) 115 (17.6)
No graduate degree 163,563 (69.3) 3,235 (77.4) 1,199 (79.1) 539 (82.4)
Deprivation –2.5 (3.6) –2.2 (4.2) –2.3 (4.1) –2.2 (3.8)
Alcohol consumption Daily or almost daily 54,261 (22.8) 990 (23.3) 311 (20.3) 152 (22.8)
3 or 4 times a week 57,255 (24.1) 814 (19.1) 313 (20.5) 117 (17.5)
1 or 2 times a week 60,106 (25.2) 952 (22.4) 357 (23.3) 147 (22.0)
1–3 times a month 24,778 (10.4) 396 (9.3) 156 (10.2) 59 (8.8)
Special occasions only 25,409 (10.7) 576 (13.5) 215 (14.1) 91 (13.6)
Never 16,239 (6.8) 524 (12.3) 177 (11.6) 101 (15.1)
Smoking Current smoker 21,470 (9.0) 413 (9.8) 115 (7.6) 74 (11.2)
Previous smoker 89,608 (37.8) 1,839 (43.4) 647 (42.6) 310 (46.8)
Non-smoker 126,288 (53.2) 1,983 (46.8) 757 (49.8) 278 (42.0)
Physical activity Strenuous 19,441 (8.7) 186 (4.9) 74 (5.2) 27 (4.7)
Moderate 148,812 (66.6) 2,350 (62.1) 908 (64.2) 359 (62.2)
Light 55,137 (24.7) 1,247 (33.0) 432 (30.6) 191 (28.6)
BMI 26.8 (5.7) 27.1 (6.0) 26.8 (5.6) 27.8 (7.1)
APOE variant 2 30,818 (13.3) 306 (8.2) 79 (5.3) 51 (7.8)
3 138,634 (59.7) 1,559 (42.0) 505 (33.6) 275 (42.1)
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sub-sample used for analyses utilizing prescription239
history (Fig. 1) were very similar to the entire sample240
(Supplementary Table 2). A total of 13,361 (5.6%)241
participants had been diagnosed with AF and among242
the 115,206 participants with data on prescriptions,243
5,513 (4.8%) had a history of being prescribed war-244
farin (Supplementary Table 3).245
There were 145,186 (61.0%) carriers of the T-allele246
in the sample: 111,756 (46.9%) were heterozygous247
for the T-allele, and 33,430 (14.0%) were homozy-248
gous for the T-allele; the allele frequencies were in249
Hardy-Weinberg equilibrium (χ2 = 0.23, df = 1, p =250
0.63). Among the participants, 4,259 (1.8%) had251
suspected general dementia, 1,531 (0.64%) had252
suspected ADem (Supplementary Table 4, Supple-253
mentary Figure 1), and 669 0.28%) had suspected254
VaD (Supplementary Table 4, Supplementary Fig-255
ure 1); 152 participants (0.03%) had been diagnosed256
with both ADem and VaD. People with at least257
one parent with dementia were more likely develop258
ADem (OR = 3.0, 95% CI = 2.6–3.4, p < 2.0 × 10–16)259
and more likely to develop VaD (OR = 2.1, 95%260
CI = 1.7–2.7, p < 1.9 × 10–9).261
rs9923231 polymorphism and warfarin dose262
Carrying the T-allele was negatively associated263
with the average dose of warfarin (perT-allele = –0.29,264
SE = 0.015, p < 2.0 × 10–16). Individuals heterozy-265
gous for the T-allele were prescribed a dose of war-266
farin that was on average 0.23 mg smaller than the267
dose prescribed to non-carriers (SE = 0.022, p <268
2.0 × 10–16), while individuals homozygous for the269
T-allele were prescribed a dose of warfarin that was270
on average 0.62 mg smaller than the dose presc-271
ribed to non-carriers (SE = 0.032, p < 2.0 × 10–16).272
The average dose of warfarin was also negatively273
associated with age ( = –0.010, SE = 2.0 × 10–3,274
p = 4.1 × 10–7), and was higher in males ( = 0.062,275
SE = 0.022, p = 5.7 × 10–3).276
rs9923231 polymorphism and dementia risk277
Parents of carriers of the T-allele were more li-278
kely to have developed dementia (additive effect279
per T-allele: OR = 1.04, 95% CI = 1.02–1.06, p = 3.7280
× 10–5). When the presence of the T-allele was used281
to predict general dementia in participants, the effect282
was not significant, nor was the effect significant283
when the presence of the T-allele was used to predict284
ADem in participants (Table 2, Fig. 2).285
Table 2
Results of the additive models with T as the effect allele, using
rs9923231 to predict parental dementia, general dementia, ADem,
and VaD
Effect per T allele
rs9923231 OR 95% CI p n cases
Parental dementia 1.04 1.02–1.06 3.7 × 10–5 34,737
General dementia 1.02 0.98–1.07 0.33 4,259
ADem 1.02 0.94–1.10 0.60 1,531
VaD 1.17 1.04–1.32 0.010 669
When limited to the specific outcome of VaD, 286
the additive effect of the T-allele was much larger 287
(OR = 1.17, 95% CI = 1.04–1.32, p = 0.010, Table 2, 288
Fig. 2). The full breakdown of all allele groups is 289
shown in Supplementary Table 5. We repeated the 290
models for VaD, with rs9923231 as a predictor and 291
with the simultaneous addition of concentration of 292
triglycerides, APOE variant, diagnoses of hyperten- 293
sion (n = 84,694), hypercholesterolemia (n = 40,363), 294
and diabetes (n = 20,990) as additional covariates. 295
While triglycerides, APOE variant, hypertension, 296
hypercholesterolemia, and diabetes were significant 297
predictors, this did not affect the relationship between 298
rs9923231 and VaD (Supplementary Table 6). Beca- 299
use of the importance of cardiovascular events in 300
the etiology of VaD, the T-allele was also used to 301
predict stroke, with the full set of covariates as 302
above. The models were not significant for ischemic 303
(n = 8,087, OR = 0.98, 95% CI = 0.94–1.01, p = 0.21), 304
nor for hemorrhagic (n = 2,146, OR = 0.94, 95% 305
CI = 0.88–1.01, p = 0.073) stroke. Due to the likely 306
causal link between WMH and dementia [19], 307
rs9923231 was related to WMH in the sample. When 308
all the above covariates were included in the model, 309
the association was significant, with the T-allele neg- 310
atively associated with WMH (beta = –2.3 × 10–8, 311
SE = 7.5 × 10–9, p = 2.8 × 10–3). 312
Warfarin use and VaD in carriers of the T-allele 313
In our sample, participants diagnosed with AF 314
were at greater risk for ADem (OR = 1.55, 95% 315
CI = 1.31–1.81, p = 1.7 × 10–7) and for VaD (OR = 316
2.92, 95% CI = 2.38–3.57, p < 2.0 × 10–16). The 317
effect remained significant for both ADem (OR = 318
1.29, 95% CI = 1.08–1.53, p = 4.5 × 10–3) and VaD 319
(OR = 2.17, 95% CI = 1.74–2.69, p = 1.9 × 10–12) 320
when APOE status, triglycerides, and diagnoses of 321
hypercholesterolemia, hypertension, and diabetes 322
were included in the model as covariates. To test 323
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with AF increases the risk of VaD, we performed a325
logistic model with AF, warfarin use, and rs9923231326
predicting VaD, with the inclusion of a 3-way interac-327
tion term between AF, warfarin, and rs9923231. The328
interaction between AF, warfarin use, and rs9923231329
was not significant (OR = 0.99, 95 % CI = 0.98–1.00,330
p = 0.063). The two-way interactions between the331
above variables were also not significant and effect332
sizes (main effects) were not substantially attenuated333
by the addition of the other variables into the mod-334
els (Supplementary Tables 7 and 8). Due to the small335
number of people with VaD and very limited statis-336
tical power for these analyses (Supplementary Text337
1), we repeated the analysis by modelling parental338
dementia as an outcome and including the 3-way339
interaction term as above; parental dementia was340
thus treated as a proxy for VaD in the participa-341
nts. The interaction between AF, warfarin use, and342
carrier-status was not significant (OR = 0.999, 95%343
CI = 0.996–1.00, p = 0.77).344
DISCUSSION345
In this study, we explored the relationship between346
suspected dementia, atrial fibrillation, warfarin use,347
and rs9923231, whose T-allele is associated with a348
reduction in the dose of warfarin [3, 7, 8]. We found349
a significant association between rs9923231 and sus-350
pected VaD, but not between rs9923231 and either351
suspected general dementia or suspected ADem.352
While AF was linked to VaD, the use of warfarin353
in patients that have AF and carry the T-allele did not354
increase the risk for VaD.355
While there have been reports of variants for mono-356
genic forms of VaD [20], data on the genetics of357
sporadic VaD are sparse. To our knowledge, only two358
GWAS have been conducted to investigate this: One359
(n = 5,700) [21] found only rs12007229 on the X-360
chromosome to be linked to incident VaD, while the361
other (n = 284) [22] did not find any significant asso-362
ciations for VaD. A systematic review of all genetic363
association studies for the broader term of vascular364
cognitive impairment found an association for 6 SNPs365
in 6 genes: APOE, ACT, ACE, MTHFR, PON1, and366
PSEN-1 [23].367
Previous research has associated variation in368
rs9923231 with warfarin dose [3, 7, 8, 24], and369
with various adiposity-related traits, such as hip cir-370
cumference, arm- and leg fat mass, and BMI (Gene371
Atlas [25]). To our knowledge the present study372
for the first time describes an association between373
rs9923231 and VaD, although it is important to note 374
that this is not at a genome-wide significant thresh- 375
old. The lack of a relationship between rs9923231 376
and either ADem or general dementia in the present 377
study suggests that the association between the T- 378
allele and ADem, as reported previously [9], might 379
have been partly due to the classification of parental 380
dementia. The UK Biobank questionnaire admin- 381
istered to participants did not distinguish between 382
different types of dementia and it is not known how 383
many of the 42,034 parents that were reportedly diag- 384
nosed with “Alzheimer’s/dementia” [9] may have 385
suffered from VaD. This hypothesis is further sup- 386
ported by the estimated effect sizes for the association 387
between rs9923231 and ADem, which were not num- 388
erically larger than those for the association between 389
rs9923231 genotype and parental dementia. Since 390
parental dementia was used as a proxy for ADem in 391
participants, the effect for ADem in participants sho- 392
uld have been substantially greater than for parental 393
dementia (even in the absence of statistical signif- 394
icance) if there truly was an association between 395
rs9923231 and ADem (as opposed to an association 396
between rs9923231 and VaD). Furthermore, in a rec- 397
ent GWAS of clinically diagnosed ADem (n = 398
94,437) [26] there was no association between rs 399
9923231 and ADem. 400
Based on our results and considering the impo- 401
rtance of cardiovascular abnormalities in the pathol- 402
ogy of dementia [10, 11], any future studies exploring 403
the association between rs9923231 and dementia 404
must strongly consider the role of cardiovascular 405
factors: The relationship between genotype and dem- 406
entia might hold only for cases of pure VaD or for 407
those in which vascular pathology represents the main 408
cause of the disorder. 409
There is an established association between dem- 410
entia and both stroke [27] and WMH [28]; thus, stroke 411
or WMH could act as mediators between rs9923231 412
genotype and VaD. However, we found no evidence 413
for a positive association between either rs9923231 414
and stroke or rs9923231and WMH. Moreover, the 415
latter association was statistically significant and neg- 416
ative in direction, suggesting participants carrying 417
the T-allele were less likely to exhibit WMH. While 418
we did not directly test for the effects of other rel- 419
evant processes, including microbleeds and covert 420
stroke, in the relationship between rs9923231 and 421
VaD, given the lack of evidence for an association 422
between rs9923231 and stroke, they are unlikely 423
to act as prominent mediators. These results fur- 424
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rs9923231 and VaD and reinforce the need for addi-426
tional studies to confirm this association and to test427
alternative mechanism distinct from stroke or WMH.428
Interplay between AF, VaD and warfarin use429
AF has been previously associated with cogni-430
tive decline and dementia. In our study, AF was431
associated with VaD and with ADem, even after con-432
trolling for hypertension and hypercholesterolemia.433
The association between AF and VaD is unsurprising,434
considering the inclusion of either vascular disease435
or history of stroke in almost all definitions of VaD436
[29]. Despite a substantial overlap of risk factors for437
AF and ADem, there is some evidence for an inde-438
pendent relationship between the two disorders [30,439
31]440
Due to the positive association between AF and441
VaD, the relationship between rs9923231 and VaD,442
and between rs9923231 and required warfarin dose,443
T-allele carriers that take warfarin to treat their AF444
might be at an increased risk of VaD than non-carriers445
due to warfarin-related brain hemorrhages. To test446
this, we studied an interaction between warfarin use,447
AF, and VKORC1 genotype with VaD. We observed448
no variation in dementia risk by different combina-449
tions of these predictors. Due to reduced coagulation450
of blood in carriers of the T-allele, these individu-451
als could be at greater risk of internal bleeding when452
taking warfarin. However, the required dose of war-453
farin is regularly estimated and adjusted using tests454
of blood coagulation and based on the results of the455
present paper, this approach is just as efficient in456
patients carrying the T-allele.457
Limitations and future directions458
The present study has the advantages of having459
used a well-characterized sample with access to both460
inpatient- and primary-care diagnoses. However, we461
acknowledge several limitations. First, despite the462
large number of people recruited to UK Biobank, the463
age range at the end of the sampling period for the464
cohort is 60–83 years, resulting in a low incidence465
and prevalence of dementia. This heavily reduced466
the size of our sample, especially when testing for467
interactions, and led to wide confidence intervals468
for the estimated odds ratios. Second, despite it not469
being the only vitamin K antagonist anticoagulant470
on the UK market, only warfarin was included in471
the analysis. Third, the dose of warfarin ingested472
by participants was assumed to correspond to the473
average of their prescribed dose, despite some indi- 474
viduals possibly taking more or less of the medicine 475
depending on their individual drug regimes. Fourth, 476
clinical diagnoses of dementia subtypes are diffi- 477
cult and are prone to errors due to the presence of 478
comorbidities and cardiovascular factors [32]. In the 479
present paper, imaging data to confirm the diagnoses 480
was unavailable and all diagnoses were based solely 481
on records from primary care and hospitals. Finally, 482
while most definitions of VaD include both dementia 483
and a history of stroke or cardiovascular disease, VaD 484
is very heterogeneous [33]; in the present study, we 485
did not explore potential mechanisms and mediators 486
of the association between rs9923231 and VaD, nor 487
did we test the relationship for different subtypes of 488
VaD. 489
The knowledge of genetic risk factors for diseases 490
enables the generation of more accurate hypothe- 491
ses about underlying biological mechanisms and 492
illuminates potential targets for pharmacological 493
intervention. Moreover, it allows for more informed 494
stratification of participants in clinical trials. Stud- 495
ies that build on our research should aim to replicate 496
the findings in a bigger sample and with greater pre- 497
cision determine the effect size for the association 498
between rs9923231 and VaD. Additionally, further 499
work is required to identify possible associations 500
between rs9923231 and features of VaD, such as lacu- 501
nar infarction, intracerebral hemorrhage, and white 502
matter hyperintensities. 503
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